Drugs / TL-925
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06225973 | Feb → Dec 2024 overdue | dry eye syndrome | Telios Pharma, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT07220408 Comparator | Oct 2025 → Feb 2026 overdue | conjunctivitis | Telios Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06686472 Comparator | Oct → Dec 2024 overdue | conjunctivitis | Telios Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06293820 Comparator | Apr → May 2024 | conjunctivitis | Telios Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06153342 Comparator | Nov 2023 → Jan 2024 | conjunctivitis | Telios Pharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05745064 Comparator | Feb → Jul 2023 | dry eye syndrome | Telios Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TL-925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220408 ↗ |
| Route | Topical | “topical ophthalmic eye drops administered bilaterally BID” NCT05745064 ↗ |